Paper Details

  1. Home
  2. Paper Details

Hesperetin-5,7,3'-O-triacetate suppresses airway hyperresponsiveness in ovalbumin-sensitized and challenged mice without reversing xylazine/ketamine-induced anesthesia in normal mice.

Author: ChenChi-Li, ChenChi-Ming, KoWun-Chang, YangYou-Lan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the therapeutic potential of hesperetin-5,7,3'-O-triacetate (HTA), a dual phosphodiesterase (PDE)3/4 inhibitor, for treating COPD. While PDE4 inhibitors are known for their emetic effects, the study found that HTA exhibited therapeutic effects without inducing vomiting.
Paper Details　
Original Abstract of the Article :
We recently reported that hesperetin-5,7,3'-O-triacetate (HTA) dually inhibited phosphodiesterase (PDE)3/4 with a therapeutic ratio of 20.8. The application and development of PDE4 inhibitors for treating asthma or COPD are limited by their side effects, such as nausea, vomiting and gastric hypersec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450382/

データ提供：米国国立医学図書館（NLM）

Hesperetin-5,7,3'-O-triacetate Suppresses Airway Hyperresponsiveness

In the vast desert of respiratory research, scientists are constantly seeking new therapies to alleviate the symptoms and improve the lives of individuals suffering from chronic respiratory diseases. This study delves into the realm of airway hyperresponsiveness, a hallmark of asthma and other respiratory conditions, investigating the potential therapeutic effects of hesperetin-5,7,3'-O-triacetate (HTA).

Hesperetin-5,7,3'-O-triacetate: A Potential Oasis in the Desert of Respiratory Disease

The authors demonstrate that HTA effectively suppresses airway hyperresponsiveness in mice without causing the unwanted side effects associated with conventional PDE4 inhibitors, such as nausea, vomiting, and gastric hypersecretion. This research suggests that HTA may offer a safer and more tolerable alternative for treating asthma and other respiratory conditions.

Navigating the Landscape of Respiratory Therapy: A Journey Through the Airways

The study highlights the importance of developing novel therapies with improved safety profiles. It underscores the need for a more nuanced approach to drug development, considering both efficacy and tolerability.

Health Implications and Lifestyle Applications: Finding Relief from Respiratory Symptoms

This research offers hope for individuals struggling with asthma and other respiratory conditions. The potential therapeutic benefits of HTA, combined with its favorable safety profile, suggest that it may offer a valuable new treatment option for these conditions.

Dr. Camel's Conclusion

This study underscores the need for ongoing research and innovation in developing new and improved therapies for respiratory diseases. The promising results with HTA suggest that we are making progress towards finding safer and more effective treatment options for individuals suffering from asthma and other respiratory conditions.
Date :
  1. Date Completed 2018-03-08
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

28558784

DOI: Digital Object Identifier

PMC5450382

Related Literature

Article Analysis
・Side Effects of roflumilast
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.